DEFTA Partners — 2025 Investments
1 investments dated 2025 · listed companies and verified rows first · show all
Aegle Therapeutics develops therapies using extracellular vesicles (EVs) isolated from mesenchymal stem cells to deliver therapeutic biomolecules to diseased and damaged cells.
BiotechHealthtechMedical DevicesWoburn, US
Shelley A. Hartman(Co-founder & CEO)inEvangelos V. Badiavas(Founder & Chief Scientific Officer)Heidi Kempinski(Chief Operational Officer)inKathleen Murphy(Head of Clinical Operations)Robert Williamson, Jr.(Executive Officer, Director)Robert Ryan(Director)
Co-investorsNew World AngelsOcean Azul PartnersDeepWork CapitalDEFTA HEALTHCARE TECHNOLOGIES
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.